Ratings Kora Saúde Participações S.A.

Equities

Delayed Sao Paulo Other stock markets 20:43:09 13/05/2024 BST			5-day change	1st Jan Change
0.69 ^BRL	-8.00%		-5.48%	-46.92%

02-28	Transcript : Kora Saúde Participações S.A., Q4 2023 Earnings Call, Feb 28, 2024
02-27	Kora Saúde Participações S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	ESG Refinitiv
KORA SAÚDE PARTICIPAÇÕES S.A.	-46.92%	106M	-
AIER EYE HOSPITAL GROUP CO., LTD.	-19.34%	16.51B	B+
BANGKOK DUSIT MEDICAL SERVICES	+5.41%	12.53B	B
IHH HEALTHCARE	+4.64%	11.74B	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+2.21%	10.06B	B+
ENCOMPASS HEALTH CORPORATION	+28.79%	8.71B	B
RAMSAY HEALTH CARE LIMITED	-3.46%	7.57B	A-
MOUWASAT MEDICAL SERVICES COMPANY	+18.60%	7.14B	D
THE ENSIGN GROUP, INC.	+4.91%	6.68B	B-
GLOBAL HEALTH LIMITED	+44.78%	4.54B	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality